Welcome to our dedicated page for Advanced Micro Devices SEC filings (Ticker: AMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Micro Devices’ disclosures are as multifaceted as its silicon roadmap. Whether you’re tracking wafer supply commitments for Ryzen CPUs, margins on Radeon GPUs, or integration costs from the Xilinx acquisition, AMD’s 10-K and 10-Q filings hold the details that move markets. Yet wading through hundreds of pages is time-consuming.
Stock Titan’s AI engine turns that problem into clarity. Our platform delivers AMD SEC filings explained simply, with sentence-level summaries layered atop the original documents. Need instant alerts on an AMD 8-K material events explained note, or to verify AMD Form 4 insider transactions real-time? We stream every submission from EDGAR within seconds, tag the numbers that matter, and surface red-flag language you might miss.
Investors use these insights to:
- Compare segment revenue and gross margin trends in each AMD quarterly earnings report 10-Q filing.
- See how stock-based awards shift in the latest AMD proxy statement executive compensation.
- Monitor AMD insider trading Form 4 transactions and set watchlists for key officers.
- Dive into capex guidance with our AMD earnings report filing analysis.
- Download an AMD annual report 10-K simplified for quick reference.
- Track large option exercises through AMD executive stock transactions Form 4.
- Ask natural questions like “understanding AMD SEC documents with AI” and get immediate answers.
No spreadsheets to build, no jargon to untangle—just the data, the context, and the confidence to act before the market fully digests AMD’s next disclosure.
Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.
- Options granted: 21,350 options to purchase common shares.
- Exercise price: $1.80 per share.
- Vesting schedule: 100% vested immediately on the grant date.
- Expiration: 06/30/2035 (10-year term).
- Post-transaction holdings: Luput now holds 21,350 derivative securities directly.
No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.